The evolution of AI, more limited-time product offerings and GLP-1 use for weight loss are among the issues expected to play a more prominent role this year.

Weight loss drugs have risen in popularity in the recent years, but a disconnect remains between those who need the drugs and ...

Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

The New Year is a time of reflection and change for many Americans, who start each January with a clean slate and goals for the next 12 months.Many resolutions ...

Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down and get fit have an ...

Trump threatened "very high" tariffs on Denmark amid Greenland dispute, raising fears of higher prices for Danish pharmaceuticals.

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...

Britain's Terry Smith made public for the first time on Thursday why his fund dumped its Diageo stake last year, citing ...

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second ...

As employers grapple with including GLP-1s in their benefits packages, they face a complex decision that boils down to two main factors: human resources and finance. On one side, there's the potential ...

More people with eating disorders are showing up across treatment settings, but doctors struggle with misconceptions and fear ...